Stockholm, 2012-12-20 15:01 CET (GLOBE NEWSWIRE) -- In consultation with the largest shareholders, the Chairman of PledPharma has established a Nomination Committee for the 2013 Annual General Meeting which is to be held on April 18. The committee consists of Staffan Persson, Peter Lindell, Gunnar Lindberg and Håkan Åström (Chairman of PledPharma). Staffan Persson will act as convenor for the Nomination Committee.
The Committee's task is to present proposals regarding Chairman and other members of the board and fees and other remuneration to the Board´s members. The Nominating Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals to the process to appoint the Nomination Committee for the AGM in 2014.
Shareholders who wish to submit proposals to the Nomination Committee can do so by e-mail: hakanastrom@aol.com
For more information please contact:
Håkan Åström, Chairman
Phone: +46 703 747 213
Jacques Näsström, CEO
Phone: +46 737 130 979
jacques.nasstrom@pledpharma.se
About PledPharma
PledPharma is a Swedish specialty pharma company that develops a new medicine, PledOx™, for prevention of the severe side effects that patients develop as a consequence of chemotherapy treatment of cancer. Many times the treatment cannot be carried out as planned due to very difficult side effects. The current market for supportive cancer care is some SEK 72 billion. PledOx is a medicine within the patent protected substance class PLED, which protects the body’s normal cells against oxidative stress. Oxidative stress is a condition where an overabundance of harmful oxygen molecules (free oxygen radicals) has been formed. We are also evaluating opportunities with PLED substances for other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se
